Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke

Summary

This study will evaluate the safety and efficacy of intravenous ex vivo cultured adult allogenic mesenchymal stem cells in patients with ischemic cerebral stroke. Patient will be given single intravenous dose of allogenic mesenchymal stem cells 2 million cells/Kg body weight or placebo within 10 days of stroke. Patients will be followed up till 12 months. Safety will be evaluated by type, number and proportion of patients with adverse events. Efficacy will be evaluated by clinical parameters and MRI.

Timeline

Start

2011-12

Primary completion

2013-05

Completion

2013-05

Outcome

Outcome not reported

Stopped (Business): “Business reasons”

Drugs

Indications